Diabetic Assays Market Synopsis

Diabetic Assays Market Size Was Valued at USD 3.23 Billion in 2023, and is Projected to Reach USD 4.81 Billion by 2032, Growing at a CAGR of 4.50% From 2024-2032.

• Diabetic assays refer to, and encompasses diagnosis and measuring equipment used for the diagnosis of Diabetes mellitus, which affects a person’s blood sugar levels. These assays include a variety of devices including glucose meter, HbA1c test, CGMS and laboratory tests, including insulin and pancreatic function as well as diabetes related complications tests. The driving forces for its market include the rising incidence of type-2 diabetes, rising knowledge about screening and treatment, technological development, and the need for portable diagnostics services. It is anticipated that with the increasing trend towards preventive medicine and the focus to deliver customized, patient specific care, the diabetic assays market will grow rapidly and prominently propose solutions for proper diabetes care.
• Thus, the market for diabetic assays has enjoyed a robust growth within the past few years as the number of diabetic patients grows globally. At present, approximately 463 million people are living with diabetes, and the need for efficient diagnostic methods and monitoring tools has rapidly increased. The growth of this industry can be as a result of increased health consciousness, technological enhancements, and increase in diseases associated with life styles. Specific market contractors are committed to creating new assays that more accurately and rapidly diagnose diabetes, for those with both type 1 and type 2 diabetes.
• The type of diabetic assays is ever evolving courtesy of technological developments such as point of care devices as well as continuous glucose monitoring systems. Recent advancements in the systems’ use of electronic tools and mobile health applications and telemedicine have taken distance management of diabetes to another level. Also, with the increasing focus on patient actualization there has been an evolution toward the development of point-of-care interest relevant assays. It is also supported by favourable government policies intended to enhance the delivery of diabetes care and a rising research and development expenditure.
• There are geographical trends about the global diabetic assays market and one finds that the North American market is leading in this context because of increased health care expenditure, better health care facilities and presence of some giants of the industry. Nonetheless, the Asia-Pacific is likely to emerge as the most rapidly growing market during the forecast period, due to increasing prevalence of diabetics and better health care access. With market evolution, companies are expected to increase M&A activities in order to expand and diversify their current and prospective product offering while establishing a strong market position. All in all, the diabetic assays market is expected to grow further by reaching new heights as the corporations continue to develop new products and professional diabetics’ care services.

Diabetic Assays Market Trend Analysis

The Rise of Continuous Glucose Monitoring Systems in Diabetes Management

• The worldwide use of CGM systems is emerging as a generational leap in diabetes care. CGM devices are different from blood glucose meters which need lancet tests for determining the blood glucose level, instead CGM devices have glucose sensors which are implanted under the skin. This constant data flow means that the patient can track their glucose levels during the day and night and, accordingly, the ability to identify deviations and prevent hypoglycemic or hyperglycemic episodes. CGM systems provide timely data providing individuals with accurate data to make decisions about food intake, physical activity or doses of insulin. Thus, the majority of patients noticed that their glycemic level was significantly enhanced, which would help to prevent further severe side effects of diabetes.
• However, the application of modern technologies, for instance, the use of mobile application in CGM systems and the cloud-based data analysis system makes it more efficient and complete type II diabetes management program. These applications enable the user to view their glucose data on easy to read dials, set for alarm for high or low glucose levels, and ensure that healthcare givers get the information provided to them easily. It provides a multidisciplinary view to the diseases and instigates care processes that allow involving patients in the creation of the optimal treatment schedule based on the information received in real-time. Also, the observed interest in AI and machine learning is expected to improve these advancements with predictive capabilities that can look into the future of glucose trends while proposing suitable action plans. In this case, transitioning from occasional checks that came with intermittent sensors to constant check-up that comes with CGMs not only benefits the unique person with diabetes but also responds with contemporary frameworks around the general concept of health care.

The Growing Shift Toward Home-Based Testing Solutions in Diabetes Management

• Mobile testing home solutions for diabetes care have emerged as a new wave towards patient self-management and preferential care. On this case, individuals with diabetes used to have to go to healthcare facilities for blood tests and check ups on a regular basis. However, the appearance of safe to use at-home diagnostic kits has changed this scenario by allowing patients to do monitoring at the comfort of their own homes. They predominate include simple devices that offer instant workout hence the ability to monitor blood glucose level without having to book appointments or receive a lab result. This convenience not only improves engagement but also empowers patients and provides them with a renewed sense of independence as reading that screen means that they can do something right away about what they’ve just read – possibly change up their diet, their exercise routine, or medication timetable.
• The on-going COVID-19 outbreak has intensified the use of home testing solutions because patients concern potential contact with the virus in clinical locations. The COVID-19 pandemic and especially social distancing have clearly pointed out the importance, the need for safe and easily accessed solutions to healthcare delivery. As a result, manufacturers have further put their focus and resources into designing better home testing kits that, in addition to being less expensive, are more accurate as well. This is not just a quick fix to patient’s requirements for care but is preparing the way for significant changes in the future of diabetes. Since the usage of telemedicine and remote health monitoring stays prevalent in healthcare, home-based testing solutions remain the promising prospect for further development of diabetic patients self-management.

Diabetic Assays Market Segment Analysis:

Diabetic Assays Market Segmented based on By Method, By Product Type, By Disease Type and By End-Users

By Method, ELISA segment is expected to dominate the market during the forecast period

• ELISA or Enzyme-Linked Immunosorbent Assay is one of the foundational tests in diabetes and holds its reputation for effectively analyzing different biomarkers associated with this disease. Through this method it is easy to establish the quantitative measurement of components such as insulin and C peptide which plays very significant role to the metabolic processes and progress of diabetes disease among patients. CO Bacigalupi, It is agreed that the measurability of these biomarkers is helpful in creating specific treatment directions as it offers healthcare professionals an opportunity to have a look at the manner and extent of insulin creation and reaction in every person. Also, ELSIA does not only endure increased sample concentration but can also handle more samples at the same time making it a highly effective approach when it comes to the throughput in laboratories. This feature is especially beneficial when many tests are performed at a single time, as is the case in research and clinical diagnosis; this leads to greater throughput and turnaround time on results that are critically essential in patient care.
• Furthermore, application of ELISA not only in daily diabetes screening but in research finding out the pathophysiology of diabetes as well as new therapeutic interventions for the disease. Science works using ELISA to explore the affinity of diverse biochemical markers in various types of diabetes that helps in understanding the disease. It is employed in laboratories as well as in surveys assessing changes in incidence and prognosis of diabetes in populations. The ELISA methods are still advancing with the enhancement of new technologies that result in high accuracy and new uses like the point of care. This keeps ELISA strategic for both clinical and research purposes in diabetes care so as to continue to form part of the general solution moving forward.

By End-Users, Hospitals segment held the largest share in 2023

• Hospitals are central to the diagnosis, treatment and ongoing care of patients with diabetes, the common endocrinopathy. The rising incidences of diabetes coupled with other related complications, which require hospital admission, have raised the need to come up with more accurate and effective ways or testing for diabetes. Health care facilities cannot afford to have diagnostic equipment that takes a long time to give results and/or produces inaccurate results. Family physicians could identify that due to time patients kept visiting the clinics with multiple complaints and may be accompanied by chronic illnesses. Due to this need for complex tests, there is support for incorporating better system technologies, including auto executed lab systems and point of cares testing tools that enhance favorable patient treatments timely.
• Furthermore, new developments in hospital laboratories are revising the therapeutic environment of diabetes. With the help of digital health solutions, electronic record of health, modern data analysis, hospitals can optimize the testing procedures and work with the patients. These innovations make it possible to track patient data, tendencies of glucose level, and to locomotor treatment settings depending on the patient. Moreover, the additional of telemedicine services helps to increase the availability of diabetes treatment and follow-up including remote monitoring and consultations. Over time, more hospitals are likely to harmonize with the changing environment and this means that the focus on implementing new testing techniques and trends will go along way in enhancing the quality of care given to those with diabetes thus a likelihood of the rate of complication to this disease reducing.

Diabetic Assays Market Regional Insights:

Asia-Pacific is Expected to Dominate the Market Over the Forecast period

• The market of diabetic assays in the Asia-Pacific region currently records a very rapid growth for two reasons: Firstly, the continually rising incidence of diabetes, especially in such large-populated countries as India and China. The countries listed in the mentioned International Diabetes Federation have a high prevalence of diabetic patients, and thus efficient solutions for screening and diagnosis are required. Due to increased costs in the health sector, governments and other private entities are pouring a lot of cash to improve the healthcare system. A Number of them is associated with equipment and supplies, which cover provision of superior diagnostic instruments, and development of diabetes care stations to enhance the diagnostic procedure. In summary, the Diabetes Assay market is growing steadily due to the demands made by patients currently living with diabetes or being at risk for developing diabetes, especially for more effective early diagnostic methods.
• In addition, increasing awareness about diabetes and its relatedcomorbidities continues serve as a major driver towards the consumption of diabetic assays in the region. Community health education with the purpose of creating awareness on prevention and control of diabetes has seen demand for health care by people rise. The market for diabetic assays is expected to grow even further because as the public becomes more informed about the continuing need to monitor and screen for diabetic symptoms, the more likely they will purchase the necessary assays for diabetic patients. At the same time, advancements in telemedicine and advanced practices in the realm of digital health are opening up more diagnostic care opportunities in remote regions and across rural areas. These developments along with growing population with diabetes mellitus and rising disposable income coupled with growing urban middle class population present a great opportunity for growth of the Asia-Pacific regional market for diabetic assays to contribute to the solutions and betterment of health care management.

Active Key Players in the Diabetic Assays Market

• Abbvie, Inc (U.S.),
• Novartis AG (Switzerland),
• Teva Pharmaceutical Industries Ltd (Israel),
• Pfizer Inc. (U.S.),
• Merck KGaA (U.S.),
• Abbott (U.S.),
• Siemens Healthcare Private Limited (Germany),
• Dynatronics Corporation (U.S.),
• BIOMÉRIEUX (France),
• Bio-Rad Laboratories, Inc. (U.S.),
• BAG Diagnostics GmbH (Germany),
• DiaSorin S.p.A. (Italy),
• DRG INSTRUMENTS GMBH (Germany),
• PTS Diagnostics (U.S.),
• Ortho Clinical Diagnostics (U.S.),
• Diazyme Laboratories, Inc. (U.S.),
• ETHOS BIOSCIENCES (U.S.),
• Abnova Corporation (Taiwan),
• Monobind Inc. (U.S.), Other Key Players

Chapter 1: Introduction
 1.1 Scope and Coverage

Chapter 2:Executive Summary

Chapter 3: Market Landscape
 3.1 Market Dynamics
  3.1.1 Drivers
  3.1.2 Restraints
  3.1.3 Opportunities
  3.1.4 Challenges
 3.2 Market Trend Analysis
 3.3 PESTLE Analysis
 3.4 Porter's Five Forces Analysis
 3.5 Industry Value Chain Analysis
 3.6 Ecosystem
 3.7 Regulatory Landscape
 3.8 Price Trend Analysis
 3.9 Patent Analysis
 3.10 Technology Evolution
 3.11 Investment Pockets
 3.12 Import-Export Analysis

Chapter 4: Diabetic Assays Market by Method
 4.1 Diabetic Assays Market Snapshot and Growth Engine
 4.2 Diabetic Assays Market Overview
 4.3 ELISA
  4.3.1 Introduction and Market Overview
  4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.3.3 Key Market Trends, Growth Factors and Opportunities
  4.3.4 ELISA: Geographic Segmentation Analysis
 4.4 Point of Care Testing
  4.4.1 Introduction and Market Overview
  4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.4.3 Key Market Trends, Growth Factors and Opportunities
  4.4.4 Point of Care Testing: Geographic Segmentation Analysis
 4.5 Enzymatic Assay
  4.5.1 Introduction and Market Overview
  4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.5.3 Key Market Trends, Growth Factors and Opportunities
  4.5.4 Enzymatic Assay: Geographic Segmentation Analysis
 4.6 Colorimetric Assay
  4.6.1 Introduction and Market Overview
  4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.6.3 Key Market Trends, Growth Factors and Opportunities
  4.6.4 Colorimetric Assay: Geographic Segmentation Analysis
 4.7 Others
  4.7.1 Introduction and Market Overview
  4.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.7.3 Key Market Trends, Growth Factors and Opportunities
  4.7.4 Others: Geographic Segmentation Analysis

Chapter 5: Diabetic Assays Market by Product Type
 5.1 Diabetic Assays Market Snapshot and Growth Engine
 5.2 Diabetic Assays Market Overview
 5.3 Instruments
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Instruments: Geographic Segmentation Analysis
 5.4 Testing Kits
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Testing Kits: Geographic Segmentation Analysis
 5.5 Reagent
  5.5.1 Introduction and Market Overview
  5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.5.3 Key Market Trends, Growth Factors and Opportunities
  5.5.4 Reagent: Geographic Segmentation Analysis

Chapter 6: Diabetic Assays Market by Disease Type
 6.1 Diabetic Assays Market Snapshot and Growth Engine
 6.2 Diabetic Assays Market Overview
 6.3 Type 1 Diabetes
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Type 1 Diabetes: Geographic Segmentation Analysis
 6.4 Type 2 Diabetes
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Type 2 Diabetes: Geographic Segmentation Analysis
 6.5 Gestational Diabetes
  6.5.1 Introduction and Market Overview
  6.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.5.3 Key Market Trends, Growth Factors and Opportunities
  6.5.4 Gestational Diabetes: Geographic Segmentation Analysis

Chapter 7: Diabetic Assays Market by End-Users
 7.1 Diabetic Assays Market Snapshot and Growth Engine
 7.2 Diabetic Assays Market Overview
 7.3 Hospitals
  7.3.1 Introduction and Market Overview
  7.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  7.3.3 Key Market Trends, Growth Factors and Opportunities
  7.3.4 Hospitals: Geographic Segmentation Analysis
 7.4 Homecare
  7.4.1 Introduction and Market Overview
  7.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  7.4.3 Key Market Trends, Growth Factors and Opportunities
  7.4.4 Homecare: Geographic Segmentation Analysis
 7.5 Specialty Clinics
  7.5.1 Introduction and Market Overview
  7.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  7.5.3 Key Market Trends, Growth Factors and Opportunities
  7.5.4 Specialty Clinics: Geographic Segmentation Analysis
 7.6 Others
  7.6.1 Introduction and Market Overview
  7.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  7.6.3 Key Market Trends, Growth Factors and Opportunities
  7.6.4 Others: Geographic Segmentation Analysis

Chapter 8: Company Profiles and Competitive Analysis
 8.1 Competitive Landscape
  8.1.1 Competitive Benchmarking
  8.1.2 Diabetic Assays Market Share by Manufacturer (2023)
  8.1.3 Industry BCG Matrix
  8.1.4 Heat Map Analysis
  8.1.5 Mergers and Acquisitions
  
 8.2 ABBVIE INC (U.S)
  8.2.1 Company Overview
  8.2.2 Key Executives
  8.2.3 Company Snapshot
  8.2.4 Role of the Company in the Market
  8.2.5 Sustainability and Social Responsibility
  8.2.6 Operating Business Segments
  8.2.7 Product Portfolio
  8.2.8 Business Performance
  8.2.9 Key Strategic Moves and Recent Developments
  8.2.10 SWOT Analysis
 8.3 NOVARTIS AG (SWITZERLAND)
 8.4 TEVA PHARMACEUTICAL INDUSTRIES LTD (ISRAEL)
 8.5 PFIZER INC (U.S)
 8.6 MERCK KGAA (U.S)
 8.7 ABBOTT (U.S)
 8.8 SIEMENS HEALTHCARE PRIVATE LIMITED (GERMANY)
 8.9 DYNATRONICS CORPORATION (U.S)
 8.10 BIOMÉRIEUX (FRANCE)
 8.11 BIO-RAD LABORATORIES INC (U.S)
 8.12 BAG DIAGNOSTICS GMBH (GERMANY)
 8.13 DIASORIN S.P.A (ITALY)
 8.14 DRG INSTRUMENTS GMBH (GERMANY)
 8.15 PTS DIAGNOSTICS (U.S)
 8.16 ORTHO CLINICAL DIAGNOSTICS (U.S)
 8.17 DIAZYME LABORATORIES INC (U.S)
 8.18 ETHOS BIOSCIENCES (U.S)
 8.19 ABNOVA CORPORATION (TAIWAN)
 8.20 MONOBIND INC (U.S)
 8.21 OTHER KEY PLAYERS

Chapter 9: Global Diabetic Assays Market By Region
 9.1 Overview
 9.2. North America Diabetic Assays Market
  9.2.1 Key Market Trends, Growth Factors and Opportunities
  9.2.2 Top Key Companies
  9.2.3 Historic and Forecasted Market Size by Segments
  9.2.4 Historic and Forecasted Market Size By Method
  9.2.4.1 ELISA
  9.2.4.2 Point of Care Testing
  9.2.4.3 Enzymatic Assay
  9.2.4.4 Colorimetric Assay
  9.2.4.5 Others
  9.2.5 Historic and Forecasted Market Size By Product Type
  9.2.5.1 Instruments
  9.2.5.2 Testing Kits
  9.2.5.3 Reagent
  9.2.6 Historic and Forecasted Market Size By Disease Type
  9.2.6.1 Type 1 Diabetes
  9.2.6.2 Type 2 Diabetes
  9.2.6.3 Gestational Diabetes
  9.2.7 Historic and Forecasted Market Size By End-Users
  9.2.7.1 Hospitals
  9.2.7.2 Homecare
  9.2.7.3 Specialty Clinics
  9.2.7.4 Others
  9.2.8 Historic and Forecast Market Size by Country
  9.2.8.1 US
  9.2.8.2 Canada
  9.2.8.3 Mexico
 9.3. Eastern Europe Diabetic Assays Market
  9.3.1 Key Market Trends, Growth Factors and Opportunities
  9.3.2 Top Key Companies
  9.3.3 Historic and Forecasted Market Size by Segments
  9.3.4 Historic and Forecasted Market Size By Method
  9.3.4.1 ELISA
  9.3.4.2 Point of Care Testing
  9.3.4.3 Enzymatic Assay
  9.3.4.4 Colorimetric Assay
  9.3.4.5 Others
  9.3.5 Historic and Forecasted Market Size By Product Type
  9.3.5.1 Instruments
  9.3.5.2 Testing Kits
  9.3.5.3 Reagent
  9.3.6 Historic and Forecasted Market Size By Disease Type
  9.3.6.1 Type 1 Diabetes
  9.3.6.2 Type 2 Diabetes
  9.3.6.3 Gestational Diabetes
  9.3.7 Historic and Forecasted Market Size By End-Users
  9.3.7.1 Hospitals
  9.3.7.2 Homecare
  9.3.7.3 Specialty Clinics
  9.3.7.4 Others
  9.3.8 Historic and Forecast Market Size by Country
  9.3.8.1 Bulgaria
  9.3.8.2 The Czech Republic
  9.3.8.3 Hungary
  9.3.8.4 Poland
  9.3.8.5 Romania
  9.3.8.6 Rest of Eastern Europe
 9.4. Western Europe Diabetic Assays Market
  9.4.1 Key Market Trends, Growth Factors and Opportunities
  9.4.2 Top Key Companies
  9.4.3 Historic and Forecasted Market Size by Segments
  9.4.4 Historic and Forecasted Market Size By Method
  9.4.4.1 ELISA
  9.4.4.2 Point of Care Testing
  9.4.4.3 Enzymatic Assay
  9.4.4.4 Colorimetric Assay
  9.4.4.5 Others
  9.4.5 Historic and Forecasted Market Size By Product Type
  9.4.5.1 Instruments
  9.4.5.2 Testing Kits
  9.4.5.3 Reagent
  9.4.6 Historic and Forecasted Market Size By Disease Type
  9.4.6.1 Type 1 Diabetes
  9.4.6.2 Type 2 Diabetes
  9.4.6.3 Gestational Diabetes
  9.4.7 Historic and Forecasted Market Size By End-Users
  9.4.7.1 Hospitals
  9.4.7.2 Homecare
  9.4.7.3 Specialty Clinics
  9.4.7.4 Others
  9.4.8 Historic and Forecast Market Size by Country
  9.4.8.1 Germany
  9.4.8.2 UK
  9.4.8.3 France
  9.4.8.4 Netherlands
  9.4.8.5 Italy
  9.4.8.6 Russia
  9.4.8.7 Spain
  9.4.8.8 Rest of Western Europe
 9.5. Asia Pacific Diabetic Assays Market
  9.5.1 Key Market Trends, Growth Factors and Opportunities
  9.5.2 Top Key Companies
  9.5.3 Historic and Forecasted Market Size by Segments
  9.5.4 Historic and Forecasted Market Size By Method
  9.5.4.1 ELISA
  9.5.4.2 Point of Care Testing
  9.5.4.3 Enzymatic Assay
  9.5.4.4 Colorimetric Assay
  9.5.4.5 Others
  9.5.5 Historic and Forecasted Market Size By Product Type
  9.5.5.1 Instruments
  9.5.5.2 Testing Kits
  9.5.5.3 Reagent
  9.5.6 Historic and Forecasted Market Size By Disease Type
  9.5.6.1 Type 1 Diabetes
  9.5.6.2 Type 2 Diabetes
  9.5.6.3 Gestational Diabetes
  9.5.7 Historic and Forecasted Market Size By End-Users
  9.5.7.1 Hospitals
  9.5.7.2 Homecare
  9.5.7.3 Specialty Clinics
  9.5.7.4 Others
  9.5.8 Historic and Forecast Market Size by Country
  9.5.8.1 China
  9.5.8.2 India
  9.5.8.3 Japan
  9.5.8.4 South Korea
  9.5.8.5 Malaysia
  9.5.8.6 Thailand
  9.5.8.7 Vietnam
  9.5.8.8 The Philippines
  9.5.8.9 Australia
  9.5.8.10 New Zealand
  9.5.8.11 Rest of APAC
 9.6. Middle East & Africa Diabetic Assays Market
  9.6.1 Key Market Trends, Growth Factors and Opportunities
  9.6.2 Top Key Companies
  9.6.3 Historic and Forecasted Market Size by Segments
  9.6.4 Historic and Forecasted Market Size By Method
  9.6.4.1 ELISA
  9.6.4.2 Point of Care Testing
  9.6.4.3 Enzymatic Assay
  9.6.4.4 Colorimetric Assay
  9.6.4.5 Others
  9.6.5 Historic and Forecasted Market Size By Product Type
  9.6.5.1 Instruments
  9.6.5.2 Testing Kits
  9.6.5.3 Reagent
  9.6.6 Historic and Forecasted Market Size By Disease Type
  9.6.6.1 Type 1 Diabetes
  9.6.6.2 Type 2 Diabetes
  9.6.6.3 Gestational Diabetes
  9.6.7 Historic and Forecasted Market Size By End-Users
  9.6.7.1 Hospitals
  9.6.7.2 Homecare
  9.6.7.3 Specialty Clinics
  9.6.7.4 Others
  9.6.8 Historic and Forecast Market Size by Country
  9.6.8.1 Turkey
  9.6.8.2 Bahrain
  9.6.8.3 Kuwait
  9.6.8.4 Saudi Arabia
  9.6.8.5 Qatar
  9.6.8.6 UAE
  9.6.8.7 Israel
  9.6.8.8 South Africa
 9.7. South America Diabetic Assays Market
  9.7.1 Key Market Trends, Growth Factors and Opportunities
  9.7.2 Top Key Companies
  9.7.3 Historic and Forecasted Market Size by Segments
  9.7.4 Historic and Forecasted Market Size By Method
  9.7.4.1 ELISA
  9.7.4.2 Point of Care Testing
  9.7.4.3 Enzymatic Assay
  9.7.4.4 Colorimetric Assay
  9.7.4.5 Others
  9.7.5 Historic and Forecasted Market Size By Product Type
  9.7.5.1 Instruments
  9.7.5.2 Testing Kits
  9.7.5.3 Reagent
  9.7.6 Historic and Forecasted Market Size By Disease Type
  9.7.6.1 Type 1 Diabetes
  9.7.6.2 Type 2 Diabetes
  9.7.6.3 Gestational Diabetes
  9.7.7 Historic and Forecasted Market Size By End-Users
  9.7.7.1 Hospitals
  9.7.7.2 Homecare
  9.7.7.3 Specialty Clinics
  9.7.7.4 Others
  9.7.8 Historic and Forecast Market Size by Country
  9.7.8.1 Brazil
  9.7.8.2 Argentina
  9.7.8.3 Rest of SA

Chapter 10 Analyst Viewpoint and Conclusion
10.1 Recommendations and Concluding Analysis
10.2 Potential Market Strategies

Chapter 11 Research Methodology
11.1 Research Process
11.2 Primary Research
11.3 Secondary Research